ml-3000 has been researched along with Arthritis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawkey, CJ; Skelly, MM | 1 |
| Evans, R | 1 |
1 review(s) available for ml-3000 and Arthritis
| Article | Year |
|---|---|
COX-LOX inhibition: current evidence for an emerging new therapy.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arthritis; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Dogs; Humans; Intestinal Mucosa; Leukotrienes; Lipoxygenase Inhibitors; Models, Animal; Peptic Ulcer; Prostaglandins; Pyrroles; Rats; Sheep | 2003 |
1 other study(ies) available for ml-3000 and Arthritis
| Article | Year |
|---|---|
Anti arthritic drugs--SMi conference: dual inhibitors. 28-29 April 2003, London, UK.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Clinical Trials as Topic; Complement Activation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Humans; Isoenzymes; Lipoxygenase Inhibitors; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrroles; Thalidomide; Tumor Necrosis Factor-alpha | 2003 |